nodes	percent_of_prediction	percent_of_DWPC	metapath
Olopatadine—CYP3A4—prostate cancer	0.202	1	CbGaD
Olopatadine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0661	0.207	CbGbCtD
Olopatadine—CYP3A4—Bicalutamide—prostate cancer	0.0347	0.109	CbGbCtD
Olopatadine—CYP3A4—Estramustine—prostate cancer	0.0323	0.101	CbGbCtD
Olopatadine—CYP3A4—Abiraterone—prostate cancer	0.0288	0.09	CbGbCtD
Olopatadine—CYP3A4—Flutamide—prostate cancer	0.0288	0.09	CbGbCtD
Olopatadine—CYP3A4—Cabazitaxel—prostate cancer	0.0213	0.0666	CbGbCtD
Olopatadine—CYP3A4—Estrone—prostate cancer	0.0208	0.0651	CbGbCtD
Olopatadine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0185	0.058	CbGbCtD
Olopatadine—CYP3A4—Conjugated Estrogens—prostate cancer	0.0136	0.0426	CbGbCtD
Olopatadine—CYP3A4—Mitoxantrone—prostate cancer	0.0124	0.0387	CbGbCtD
Olopatadine—CYP3A4—Estradiol—prostate cancer	0.012	0.0374	CbGbCtD
Olopatadine—CYP3A4—Prednisone—prostate cancer	0.0103	0.0321	CbGbCtD
Olopatadine—S100A2—prostate gland—prostate cancer	0.00804	0.0778	CbGeAlD
Olopatadine—CYP3A4—Etoposide—prostate cancer	0.0078	0.0244	CbGbCtD
Olopatadine—S100A1—prostate gland—prostate cancer	0.0074	0.0717	CbGeAlD
Olopatadine—CYP3A4—Docetaxel—prostate cancer	0.00714	0.0223	CbGbCtD
Olopatadine—S100A2—seminal vesicle—prostate cancer	0.0068	0.0658	CbGeAlD
Olopatadine—S100A13—prostate gland—prostate cancer	0.00657	0.0636	CbGeAlD
Olopatadine—S100A12—prostate gland—prostate cancer	0.00648	0.0627	CbGeAlD
Olopatadine—S100A2—epithelium—prostate cancer	0.0059	0.0572	CbGeAlD
Olopatadine—S100A2—renal system—prostate cancer	0.00548	0.053	CbGeAlD
Olopatadine—S100A2—urethra—prostate cancer	0.00538	0.0521	CbGeAlD
Olopatadine—CYP3A4—Doxorubicin—prostate cancer	0.00532	0.0166	CbGbCtD
Olopatadine—S100A1—renal system—prostate cancer	0.00504	0.0489	CbGeAlD
Olopatadine—S100A13—epithelium—prostate cancer	0.00482	0.0467	CbGeAlD
Olopatadine—S100A12—epithelium—prostate cancer	0.00476	0.0461	CbGeAlD
Olopatadine—S100A13—renal system—prostate cancer	0.00447	0.0433	CbGeAlD
Olopatadine—S100A2—testis—prostate cancer	0.00354	0.0343	CbGeAlD
Olopatadine—S100A12—bone marrow—prostate cancer	0.00334	0.0323	CbGeAlD
Olopatadine—S100A1—testis—prostate cancer	0.00326	0.0316	CbGeAlD
Olopatadine—S100A13—testis—prostate cancer	0.00289	0.028	CbGeAlD
Olopatadine—S100A12—testis—prostate cancer	0.00285	0.0276	CbGeAlD
Olopatadine—CYP3A4—urine—prostate cancer	0.00282	0.0273	CbGeAlD
Olopatadine—S100A1—lymph node—prostate cancer	0.00236	0.0229	CbGeAlD
Olopatadine—S100A13—lymph node—prostate cancer	0.0021	0.0203	CbGeAlD
Olopatadine—S100A12—lymph node—prostate cancer	0.00207	0.02	CbGeAlD
Olopatadine—S100B—lymph node—prostate cancer	0.00204	0.0198	CbGeAlD
Olopatadine—S100A13—Estriol—Estramustine—prostate cancer	0.00145	0.272	CbGdCrCtD
Olopatadine—HRH1—prostate gland—prostate cancer	0.00131	0.0127	CbGeAlD
Olopatadine—S100A13—Estriol—Estrone—prostate cancer	0.00115	0.216	CbGdCrCtD
Olopatadine—S100A13—Estriol—Conjugated Estrogens—prostate cancer	0.00101	0.19	CbGdCrCtD
Olopatadine—HRH1—epithelium—prostate cancer	0.000963	0.00933	CbGeAlD
Olopatadine—HRH1—urethra—prostate cancer	0.000878	0.0085	CbGeAlD
Olopatadine—S100A13—Estriol—Estradiol—prostate cancer	0.000871	0.163	CbGdCrCtD
Olopatadine—S100A13—Estriol—Ethinyl Estradiol—prostate cancer	0.00085	0.16	CbGdCrCtD
Olopatadine—CYP3A4—renal system—prostate cancer	0.000691	0.00669	CbGeAlD
Olopatadine—HRH1—testis—prostate cancer	0.000578	0.00559	CbGeAlD
Olopatadine—HRH1—lymph node—prostate cancer	0.000419	0.00405	CbGeAlD
Olopatadine—Acepromazine—SLC22A1—prostate cancer	0.000387	0.0995	CrCbGaD
Olopatadine—Thiothixene—SLC22A1—prostate cancer	0.000372	0.0957	CrCbGaD
Olopatadine—Clomipramine—GSTP1—prostate cancer	0.000318	0.0818	CrCbGaD
Olopatadine—Imipramine—SLC22A3—prostate cancer	0.00028	0.072	CrCbGaD
Olopatadine—Imipramine—CYP2C18—prostate cancer	0.000246	0.0632	CrCbGaD
Olopatadine—Nortriptyline—CYP3A5—prostate cancer	0.000232	0.0597	CrCbGaD
Olopatadine—Imipramine—SLC22A1—prostate cancer	0.000201	0.0516	CrCbGaD
Olopatadine—Cyclobenzaprine—CYP3A4—prostate cancer	0.000196	0.0503	CrCbGaD
Olopatadine—Clomipramine—CYP2C19—prostate cancer	0.000162	0.0416	CrCbGaD
Olopatadine—Amitriptyline—CYP3A5—prostate cancer	0.000161	0.0414	CrCbGaD
Olopatadine—Nortriptyline—CYP2E1—prostate cancer	0.000159	0.041	CrCbGaD
Olopatadine—Nortriptyline—CYP2C19—prostate cancer	0.000158	0.0406	CrCbGaD
Olopatadine—Doxepin—CYP2C19—prostate cancer	0.000142	0.0364	CrCbGaD
Olopatadine—Pain—Mitoxantrone—prostate cancer	0.00014	0.000641	CcSEcCtD
Olopatadine—Rash—Goserelin—prostate cancer	0.00014	0.00064	CcSEcCtD
Olopatadine—Dermatitis—Goserelin—prostate cancer	0.000139	0.00064	CcSEcCtD
Olopatadine—Vomiting—Conjugated Estrogens—prostate cancer	0.000139	0.000639	CcSEcCtD
Olopatadine—Immune system disorder—Capecitabine—prostate cancer	0.000139	0.000638	CcSEcCtD
Olopatadine—Mediastinal disorder—Capecitabine—prostate cancer	0.000139	0.000637	CcSEcCtD
Olopatadine—Abdominal pain—Estradiol—prostate cancer	0.000139	0.000636	CcSEcCtD
Olopatadine—Body temperature increased—Estradiol—prostate cancer	0.000139	0.000636	CcSEcCtD
Olopatadine—Nasopharyngitis—Epirubicin—prostate cancer	0.000139	0.000636	CcSEcCtD
Olopatadine—Headache—Goserelin—prostate cancer	0.000139	0.000636	CcSEcCtD
Olopatadine—Erythema—Docetaxel—prostate cancer	0.000138	0.000635	CcSEcCtD
Olopatadine—Rash—Conjugated Estrogens—prostate cancer	0.000138	0.000634	CcSEcCtD
Olopatadine—Dermatitis—Conjugated Estrogens—prostate cancer	0.000138	0.000634	CcSEcCtD
Olopatadine—Headache—Conjugated Estrogens—prostate cancer	0.000137	0.00063	CcSEcCtD
Olopatadine—Dysgeusia—Docetaxel—prostate cancer	0.000136	0.000622	CcSEcCtD
Olopatadine—Infection—Etoposide—prostate cancer	0.000135	0.00062	CcSEcCtD
Olopatadine—Feeling abnormal—Mitoxantrone—prostate cancer	0.000135	0.000618	CcSEcCtD
Olopatadine—Erythema—Capecitabine—prostate cancer	0.000134	0.000615	CcSEcCtD
Olopatadine—Influenza—Epirubicin—prostate cancer	0.000134	0.000615	CcSEcCtD
Olopatadine—Back pain—Docetaxel—prostate cancer	0.000134	0.000614	CcSEcCtD
Olopatadine—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000134	0.000613	CcSEcCtD
Olopatadine—Muscle spasms—Docetaxel—prostate cancer	0.000133	0.000611	CcSEcCtD
Olopatadine—Skin disorder—Etoposide—prostate cancer	0.000132	0.000606	CcSEcCtD
Olopatadine—Dry skin—Doxorubicin—prostate cancer	0.000132	0.000603	CcSEcCtD
Olopatadine—Nausea—Goserelin—prostate cancer	0.000131	0.000603	CcSEcCtD
Olopatadine—Dysgeusia—Capecitabine—prostate cancer	0.000131	0.000602	CcSEcCtD
Olopatadine—Nausea—Conjugated Estrogens—prostate cancer	0.00013	0.000597	CcSEcCtD
Olopatadine—Back pain—Capecitabine—prostate cancer	0.00013	0.000595	CcSEcCtD
Olopatadine—Hypersensitivity—Estradiol—prostate cancer	0.000129	0.000593	CcSEcCtD
Olopatadine—Abdominal pain—Mitoxantrone—prostate cancer	0.000129	0.000593	CcSEcCtD
Olopatadine—Body temperature increased—Mitoxantrone—prostate cancer	0.000129	0.000593	CcSEcCtD
Olopatadine—Muscle spasms—Capecitabine—prostate cancer	0.000129	0.000591	CcSEcCtD
Olopatadine—Nasopharyngitis—Doxorubicin—prostate cancer	0.000128	0.000589	CcSEcCtD
Olopatadine—Eye disorder—Prednisone—prostate cancer	0.000128	0.000588	CcSEcCtD
Olopatadine—Vision blurred—Capecitabine—prostate cancer	0.000126	0.00058	CcSEcCtD
Olopatadine—Asthenia—Estradiol—prostate cancer	0.000126	0.000578	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Epirubicin—prostate cancer	0.000125	0.000572	CcSEcCtD
Olopatadine—Ill-defined disorder—Capecitabine—prostate cancer	0.000124	0.000571	CcSEcCtD
Olopatadine—Pruritus—Estradiol—prostate cancer	0.000124	0.000569	CcSEcCtD
Olopatadine—Influenza—Doxorubicin—prostate cancer	0.000124	0.000569	CcSEcCtD
Olopatadine—Immune system disorder—Prednisone—prostate cancer	0.000124	0.000568	CcSEcCtD
Olopatadine—Weight increased—Epirubicin—prostate cancer	0.000122	0.00056	CcSEcCtD
Olopatadine—Dyspnoea—Etoposide—prostate cancer	0.000121	0.000556	CcSEcCtD
Olopatadine—Malaise—Capecitabine—prostate cancer	0.000121	0.000555	CcSEcCtD
Olopatadine—Somnolence—Etoposide—prostate cancer	0.000121	0.000555	CcSEcCtD
Olopatadine—Cough—Docetaxel—prostate cancer	0.000121	0.000554	CcSEcCtD
Olopatadine—Hypersensitivity—Mitoxantrone—prostate cancer	0.00012	0.000553	CcSEcCtD
Olopatadine—Diarrhoea—Estradiol—prostate cancer	0.00012	0.000551	CcSEcCtD
Olopatadine—Infestation—Epirubicin—prostate cancer	0.00012	0.000548	CcSEcCtD
Olopatadine—Infestation NOS—Epirubicin—prostate cancer	0.00012	0.000548	CcSEcCtD
Olopatadine—Erythema—Prednisone—prostate cancer	0.000119	0.000548	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Etoposide—prostate cancer	0.000117	0.000539	CcSEcCtD
Olopatadine—Asthenia—Mitoxantrone—prostate cancer	0.000117	0.000538	CcSEcCtD
Olopatadine—Fatigue—Etoposide—prostate cancer	0.000117	0.000538	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000117	0.000537	CcSEcCtD
Olopatadine—Cough—Capecitabine—prostate cancer	0.000117	0.000537	CcSEcCtD
Olopatadine—Pain—Etoposide—prostate cancer	0.000116	0.000533	CcSEcCtD
Olopatadine—Conjunctivitis—Epirubicin—prostate cancer	0.000116	0.000533	CcSEcCtD
Olopatadine—Urinary tract infection—Epirubicin—prostate cancer	0.000116	0.000533	CcSEcCtD
Olopatadine—Dizziness—Estradiol—prostate cancer	0.000116	0.000532	CcSEcCtD
Olopatadine—Dry mouth—Docetaxel—prostate cancer	0.000115	0.000529	CcSEcCtD
Olopatadine—Upper respiratory tract infection—Doxorubicin—prostate cancer	0.000115	0.000529	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000113	0.00052	CcSEcCtD
Olopatadine—Oedema—Docetaxel—prostate cancer	0.000113	0.000518	CcSEcCtD
Olopatadine—Weight increased—Doxorubicin—prostate cancer	0.000113	0.000518	CcSEcCtD
Olopatadine—Discomfort—Capecitabine—prostate cancer	0.000113	0.000517	CcSEcCtD
Olopatadine—Epistaxis—Epirubicin—prostate cancer	0.000113	0.000517	CcSEcCtD
Olopatadine—Vision blurred—Prednisone—prostate cancer	0.000113	0.000516	CcSEcCtD
Olopatadine—Infection—Docetaxel—prostate cancer	0.000112	0.000515	CcSEcCtD
Olopatadine—Sinusitis—Epirubicin—prostate cancer	0.000112	0.000514	CcSEcCtD
Olopatadine—Feeling abnormal—Etoposide—prostate cancer	0.000112	0.000514	CcSEcCtD
Olopatadine—Diarrhoea—Mitoxantrone—prostate cancer	0.000112	0.000513	CcSEcCtD
Olopatadine—Dry mouth—Capecitabine—prostate cancer	0.000112	0.000512	CcSEcCtD
Olopatadine—Vomiting—Estradiol—prostate cancer	0.000112	0.000512	CcSEcCtD
Olopatadine—Imipramine—CYP2E1—prostate cancer	0.000111	0.0286	CrCbGaD
Olopatadine—Gastrointestinal pain—Etoposide—prostate cancer	0.000111	0.00051	CcSEcCtD
Olopatadine—Nervous system disorder—Docetaxel—prostate cancer	0.000111	0.000508	CcSEcCtD
Olopatadine—Ill-defined disorder—Prednisone—prostate cancer	0.000111	0.000508	CcSEcCtD
Olopatadine—Rash—Estradiol—prostate cancer	0.000111	0.000508	CcSEcCtD
Olopatadine—Amitriptyline—CYP2E1—prostate cancer	0.000111	0.0285	CrCbGaD
Olopatadine—Infestation NOS—Doxorubicin—prostate cancer	0.000111	0.000507	CcSEcCtD
Olopatadine—Infestation—Doxorubicin—prostate cancer	0.000111	0.000507	CcSEcCtD
Olopatadine—Dermatitis—Estradiol—prostate cancer	0.000111	0.000507	CcSEcCtD
Olopatadine—Imipramine—CYP2C19—prostate cancer	0.00011	0.0284	CrCbGaD
Olopatadine—Headache—Estradiol—prostate cancer	0.00011	0.000504	CcSEcCtD
Olopatadine—Skin disorder—Docetaxel—prostate cancer	0.00011	0.000504	CcSEcCtD
Olopatadine—Amitriptyline—CYP2C19—prostate cancer	0.00011	0.0282	CrCbGaD
Olopatadine—Oedema—Capecitabine—prostate cancer	0.000109	0.000502	CcSEcCtD
Olopatadine—Infection—Capecitabine—prostate cancer	0.000109	0.000499	CcSEcCtD
Olopatadine—Malaise—Prednisone—prostate cancer	0.000108	0.000494	CcSEcCtD
Olopatadine—Rhinitis—Epirubicin—prostate cancer	0.000108	0.000493	CcSEcCtD
Olopatadine—Abdominal pain—Etoposide—prostate cancer	0.000108	0.000493	CcSEcCtD
Olopatadine—Body temperature increased—Etoposide—prostate cancer	0.000108	0.000493	CcSEcCtD
Olopatadine—Conjunctivitis—Doxorubicin—prostate cancer	0.000107	0.000493	CcSEcCtD
Olopatadine—Urinary tract infection—Doxorubicin—prostate cancer	0.000107	0.000493	CcSEcCtD
Olopatadine—Nervous system disorder—Capecitabine—prostate cancer	0.000107	0.000492	CcSEcCtD
Olopatadine—Hypoaesthesia—Epirubicin—prostate cancer	0.000107	0.00049	CcSEcCtD
Olopatadine—Pharyngitis—Epirubicin—prostate cancer	0.000106	0.000489	CcSEcCtD
Olopatadine—Skin disorder—Capecitabine—prostate cancer	0.000106	0.000488	CcSEcCtD
Olopatadine—Epistaxis—Doxorubicin—prostate cancer	0.000104	0.000479	CcSEcCtD
Olopatadine—Nausea—Estradiol—prostate cancer	0.000104	0.000478	CcSEcCtD
Olopatadine—Vomiting—Mitoxantrone—prostate cancer	0.000104	0.000477	CcSEcCtD
Olopatadine—Sinusitis—Doxorubicin—prostate cancer	0.000104	0.000476	CcSEcCtD
Olopatadine—Visual impairment—Epirubicin—prostate cancer	0.000103	0.000474	CcSEcCtD
Olopatadine—Rash—Mitoxantrone—prostate cancer	0.000103	0.000473	CcSEcCtD
Olopatadine—Dermatitis—Mitoxantrone—prostate cancer	0.000103	0.000472	CcSEcCtD
Olopatadine—Clomipramine—CYP3A4—prostate cancer	0.000103	0.0264	CrCbGaD
Olopatadine—Headache—Mitoxantrone—prostate cancer	0.000102	0.00047	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000101	0.000463	CcSEcCtD
Olopatadine—Dyspnoea—Docetaxel—prostate cancer	0.000101	0.000462	CcSEcCtD
Olopatadine—Somnolence—Docetaxel—prostate cancer	0.0001	0.000461	CcSEcCtD
Olopatadine—Discomfort—Prednisone—prostate cancer	0.0001	0.000461	CcSEcCtD
Olopatadine—Nortriptyline—CYP3A4—prostate cancer	0.0001	0.0258	CrCbGaD
Olopatadine—Eye disorder—Epirubicin—prostate cancer	0.0001	0.00046	CcSEcCtD
Olopatadine—Hypersensitivity—Etoposide—prostate cancer	0.0001	0.00046	CcSEcCtD
Olopatadine—Rhinitis—Doxorubicin—prostate cancer	9.95e-05	0.000457	CcSEcCtD
Olopatadine—Hypoaesthesia—Doxorubicin—prostate cancer	9.88e-05	0.000453	CcSEcCtD
Olopatadine—Pharyngitis—Doxorubicin—prostate cancer	9.85e-05	0.000452	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Docetaxel—prostate cancer	9.76e-05	0.000448	CcSEcCtD
Olopatadine—Asthenia—Etoposide—prostate cancer	9.76e-05	0.000448	CcSEcCtD
Olopatadine—Dyspnoea—Capecitabine—prostate cancer	9.76e-05	0.000448	CcSEcCtD
Olopatadine—Oedema—Prednisone—prostate cancer	9.75e-05	0.000447	CcSEcCtD
Olopatadine—Fatigue—Docetaxel—prostate cancer	9.74e-05	0.000447	CcSEcCtD
Olopatadine—Nausea—Mitoxantrone—prostate cancer	9.71e-05	0.000445	CcSEcCtD
Olopatadine—Immune system disorder—Epirubicin—prostate cancer	9.69e-05	0.000445	CcSEcCtD
Olopatadine—Infection—Prednisone—prostate cancer	9.68e-05	0.000444	CcSEcCtD
Olopatadine—Mediastinal disorder—Epirubicin—prostate cancer	9.67e-05	0.000444	CcSEcCtD
Olopatadine—Pain—Docetaxel—prostate cancer	9.66e-05	0.000443	CcSEcCtD
Olopatadine—Pruritus—Etoposide—prostate cancer	9.62e-05	0.000441	CcSEcCtD
Olopatadine—Visual impairment—Doxorubicin—prostate cancer	9.57e-05	0.000439	CcSEcCtD
Olopatadine—Nervous system disorder—Prednisone—prostate cancer	9.56e-05	0.000438	CcSEcCtD
Olopatadine—Skin disorder—Prednisone—prostate cancer	9.47e-05	0.000434	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Capecitabine—prostate cancer	9.45e-05	0.000433	CcSEcCtD
Olopatadine—Fatigue—Capecitabine—prostate cancer	9.43e-05	0.000433	CcSEcCtD
Olopatadine—Pain—Capecitabine—prostate cancer	9.36e-05	0.000429	CcSEcCtD
Olopatadine—Erythema—Epirubicin—prostate cancer	9.34e-05	0.000428	CcSEcCtD
Olopatadine—Feeling abnormal—Docetaxel—prostate cancer	9.31e-05	0.000427	CcSEcCtD
Olopatadine—Diarrhoea—Etoposide—prostate cancer	9.3e-05	0.000427	CcSEcCtD
Olopatadine—Eye disorder—Doxorubicin—prostate cancer	9.28e-05	0.000426	CcSEcCtD
Olopatadine—Gastrointestinal pain—Docetaxel—prostate cancer	9.24e-05	0.000424	CcSEcCtD
Olopatadine—Dysgeusia—Epirubicin—prostate cancer	9.15e-05	0.00042	CcSEcCtD
Olopatadine—Back pain—Epirubicin—prostate cancer	9.03e-05	0.000414	CcSEcCtD
Olopatadine—Feeling abnormal—Capecitabine—prostate cancer	9.02e-05	0.000414	CcSEcCtD
Olopatadine—Doxepin—CYP3A4—prostate cancer	9.01e-05	0.0232	CrCbGaD
Olopatadine—Dizziness—Etoposide—prostate cancer	8.99e-05	0.000413	CcSEcCtD
Olopatadine—Muscle spasms—Epirubicin—prostate cancer	8.98e-05	0.000412	CcSEcCtD
Olopatadine—Immune system disorder—Doxorubicin—prostate cancer	8.97e-05	0.000411	CcSEcCtD
Olopatadine—Gastrointestinal pain—Capecitabine—prostate cancer	8.95e-05	0.00041	CcSEcCtD
Olopatadine—Mediastinal disorder—Doxorubicin—prostate cancer	8.95e-05	0.00041	CcSEcCtD
Olopatadine—Abdominal pain—Docetaxel—prostate cancer	8.93e-05	0.00041	CcSEcCtD
Olopatadine—Body temperature increased—Docetaxel—prostate cancer	8.93e-05	0.00041	CcSEcCtD
Olopatadine—Vision blurred—Epirubicin—prostate cancer	8.8e-05	0.000404	CcSEcCtD
Olopatadine—Ill-defined disorder—Epirubicin—prostate cancer	8.67e-05	0.000398	CcSEcCtD
Olopatadine—Abdominal pain—Capecitabine—prostate cancer	8.65e-05	0.000397	CcSEcCtD
Olopatadine—Body temperature increased—Capecitabine—prostate cancer	8.65e-05	0.000397	CcSEcCtD
Olopatadine—Vomiting—Etoposide—prostate cancer	8.65e-05	0.000397	CcSEcCtD
Olopatadine—Erythema—Doxorubicin—prostate cancer	8.64e-05	0.000396	CcSEcCtD
Olopatadine—Rash—Etoposide—prostate cancer	8.57e-05	0.000393	CcSEcCtD
Olopatadine—Dermatitis—Etoposide—prostate cancer	8.57e-05	0.000393	CcSEcCtD
Olopatadine—Headache—Etoposide—prostate cancer	8.52e-05	0.000391	CcSEcCtD
Olopatadine—Dysgeusia—Doxorubicin—prostate cancer	8.46e-05	0.000388	CcSEcCtD
Olopatadine—Malaise—Epirubicin—prostate cancer	8.42e-05	0.000386	CcSEcCtD
Olopatadine—Fatigue—Prednisone—prostate cancer	8.4e-05	0.000385	CcSEcCtD
Olopatadine—Back pain—Doxorubicin—prostate cancer	8.36e-05	0.000383	CcSEcCtD
Olopatadine—Hypersensitivity—Docetaxel—prostate cancer	8.33e-05	0.000382	CcSEcCtD
Olopatadine—Muscle spasms—Doxorubicin—prostate cancer	8.31e-05	0.000381	CcSEcCtD
Olopatadine—Cough—Epirubicin—prostate cancer	8.15e-05	0.000374	CcSEcCtD
Olopatadine—Vision blurred—Doxorubicin—prostate cancer	8.14e-05	0.000374	CcSEcCtD
Olopatadine—Asthenia—Docetaxel—prostate cancer	8.11e-05	0.000372	CcSEcCtD
Olopatadine—Nausea—Etoposide—prostate cancer	8.08e-05	0.000371	CcSEcCtD
Olopatadine—Hypersensitivity—Capecitabine—prostate cancer	8.06e-05	0.00037	CcSEcCtD
Olopatadine—Feeling abnormal—Prednisone—prostate cancer	8.03e-05	0.000368	CcSEcCtD
Olopatadine—Ill-defined disorder—Doxorubicin—prostate cancer	8.02e-05	0.000368	CcSEcCtD
Olopatadine—Pruritus—Docetaxel—prostate cancer	8e-05	0.000367	CcSEcCtD
Olopatadine—Gastrointestinal pain—Prednisone—prostate cancer	7.97e-05	0.000366	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	7.9e-05	0.000362	CcSEcCtD
Olopatadine—Discomfort—Epirubicin—prostate cancer	7.86e-05	0.00036	CcSEcCtD
Olopatadine—Asthenia—Capecitabine—prostate cancer	7.85e-05	0.00036	CcSEcCtD
Olopatadine—Malaise—Doxorubicin—prostate cancer	7.79e-05	0.000358	CcSEcCtD
Olopatadine—Dry mouth—Epirubicin—prostate cancer	7.78e-05	0.000357	CcSEcCtD
Olopatadine—Pruritus—Capecitabine—prostate cancer	7.74e-05	0.000355	CcSEcCtD
Olopatadine—Diarrhoea—Docetaxel—prostate cancer	7.73e-05	0.000355	CcSEcCtD
Olopatadine—Abdominal pain—Prednisone—prostate cancer	7.7e-05	0.000353	CcSEcCtD
Olopatadine—Body temperature increased—Prednisone—prostate cancer	7.7e-05	0.000353	CcSEcCtD
Olopatadine—Oedema—Epirubicin—prostate cancer	7.62e-05	0.00035	CcSEcCtD
Olopatadine—Infection—Epirubicin—prostate cancer	7.57e-05	0.000347	CcSEcCtD
Olopatadine—Cough—Doxorubicin—prostate cancer	7.54e-05	0.000346	CcSEcCtD
Olopatadine—Diarrhoea—Capecitabine—prostate cancer	7.49e-05	0.000343	CcSEcCtD
Olopatadine—Nervous system disorder—Epirubicin—prostate cancer	7.48e-05	0.000343	CcSEcCtD
Olopatadine—Dizziness—Docetaxel—prostate cancer	7.47e-05	0.000343	CcSEcCtD
Olopatadine—Skin disorder—Epirubicin—prostate cancer	7.4e-05	0.00034	CcSEcCtD
Olopatadine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	7.31e-05	0.000335	CcSEcCtD
Olopatadine—Discomfort—Doxorubicin—prostate cancer	7.27e-05	0.000333	CcSEcCtD
Olopatadine—Dizziness—Capecitabine—prostate cancer	7.24e-05	0.000332	CcSEcCtD
Olopatadine—Dry mouth—Doxorubicin—prostate cancer	7.2e-05	0.00033	CcSEcCtD
Olopatadine—Vomiting—Docetaxel—prostate cancer	7.19e-05	0.00033	CcSEcCtD
Olopatadine—Hypersensitivity—Prednisone—prostate cancer	7.18e-05	0.000329	CcSEcCtD
Olopatadine—Rash—Docetaxel—prostate cancer	7.13e-05	0.000327	CcSEcCtD
Olopatadine—Dermatitis—Docetaxel—prostate cancer	7.12e-05	0.000327	CcSEcCtD
Olopatadine—Headache—Docetaxel—prostate cancer	7.08e-05	0.000325	CcSEcCtD
Olopatadine—Oedema—Doxorubicin—prostate cancer	7.05e-05	0.000324	CcSEcCtD
Olopatadine—Imipramine—CYP3A4—prostate cancer	7.01e-05	0.018	CrCbGaD
Olopatadine—Infection—Doxorubicin—prostate cancer	7.01e-05	0.000321	CcSEcCtD
Olopatadine—Asthenia—Prednisone—prostate cancer	6.99e-05	0.000321	CcSEcCtD
Olopatadine—Amitriptyline—CYP3A4—prostate cancer	6.97e-05	0.0179	CrCbGaD
Olopatadine—Vomiting—Capecitabine—prostate cancer	6.96e-05	0.000319	CcSEcCtD
Olopatadine—Nervous system disorder—Doxorubicin—prostate cancer	6.92e-05	0.000317	CcSEcCtD
Olopatadine—Rash—Capecitabine—prostate cancer	6.9e-05	0.000316	CcSEcCtD
Olopatadine—Pruritus—Prednisone—prostate cancer	6.9e-05	0.000316	CcSEcCtD
Olopatadine—Dermatitis—Capecitabine—prostate cancer	6.89e-05	0.000316	CcSEcCtD
Olopatadine—Headache—Capecitabine—prostate cancer	6.85e-05	0.000314	CcSEcCtD
Olopatadine—Skin disorder—Doxorubicin—prostate cancer	6.85e-05	0.000314	CcSEcCtD
Olopatadine—Dyspnoea—Epirubicin—prostate cancer	6.8e-05	0.000312	CcSEcCtD
Olopatadine—Somnolence—Epirubicin—prostate cancer	6.78e-05	0.000311	CcSEcCtD
Olopatadine—Nausea—Docetaxel—prostate cancer	6.71e-05	0.000308	CcSEcCtD
Olopatadine—Diarrhoea—Prednisone—prostate cancer	6.67e-05	0.000306	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Epirubicin—prostate cancer	6.58e-05	0.000302	CcSEcCtD
Olopatadine—Fatigue—Epirubicin—prostate cancer	6.57e-05	0.000301	CcSEcCtD
Olopatadine—Pain—Epirubicin—prostate cancer	6.52e-05	0.000299	CcSEcCtD
Olopatadine—Nausea—Capecitabine—prostate cancer	6.5e-05	0.000298	CcSEcCtD
Olopatadine—Dizziness—Prednisone—prostate cancer	6.45e-05	0.000296	CcSEcCtD
Olopatadine—Dyspnoea—Doxorubicin—prostate cancer	6.29e-05	0.000288	CcSEcCtD
Olopatadine—Feeling abnormal—Epirubicin—prostate cancer	6.28e-05	0.000288	CcSEcCtD
Olopatadine—Somnolence—Doxorubicin—prostate cancer	6.27e-05	0.000288	CcSEcCtD
Olopatadine—Gastrointestinal pain—Epirubicin—prostate cancer	6.23e-05	0.000286	CcSEcCtD
Olopatadine—Vomiting—Prednisone—prostate cancer	6.2e-05	0.000284	CcSEcCtD
Olopatadine—Rash—Prednisone—prostate cancer	6.15e-05	0.000282	CcSEcCtD
Olopatadine—Dermatitis—Prednisone—prostate cancer	6.14e-05	0.000282	CcSEcCtD
Olopatadine—Headache—Prednisone—prostate cancer	6.11e-05	0.00028	CcSEcCtD
Olopatadine—Gastrointestinal disorder—Doxorubicin—prostate cancer	6.09e-05	0.000279	CcSEcCtD
Olopatadine—Fatigue—Doxorubicin—prostate cancer	6.08e-05	0.000279	CcSEcCtD
Olopatadine—Pain—Doxorubicin—prostate cancer	6.03e-05	0.000277	CcSEcCtD
Olopatadine—Abdominal pain—Epirubicin—prostate cancer	6.03e-05	0.000276	CcSEcCtD
Olopatadine—Body temperature increased—Epirubicin—prostate cancer	6.03e-05	0.000276	CcSEcCtD
Olopatadine—Feeling abnormal—Doxorubicin—prostate cancer	5.81e-05	0.000267	CcSEcCtD
Olopatadine—Nausea—Prednisone—prostate cancer	5.79e-05	0.000266	CcSEcCtD
Olopatadine—Gastrointestinal pain—Doxorubicin—prostate cancer	5.77e-05	0.000265	CcSEcCtD
Olopatadine—Hypersensitivity—Epirubicin—prostate cancer	5.62e-05	0.000258	CcSEcCtD
Olopatadine—Abdominal pain—Doxorubicin—prostate cancer	5.58e-05	0.000256	CcSEcCtD
Olopatadine—Body temperature increased—Doxorubicin—prostate cancer	5.58e-05	0.000256	CcSEcCtD
Olopatadine—Asthenia—Epirubicin—prostate cancer	5.47e-05	0.000251	CcSEcCtD
Olopatadine—Pruritus—Epirubicin—prostate cancer	5.39e-05	0.000247	CcSEcCtD
Olopatadine—Diarrhoea—Epirubicin—prostate cancer	5.22e-05	0.000239	CcSEcCtD
Olopatadine—Hypersensitivity—Doxorubicin—prostate cancer	5.2e-05	0.000238	CcSEcCtD
Olopatadine—Asthenia—Doxorubicin—prostate cancer	5.06e-05	0.000232	CcSEcCtD
Olopatadine—Dizziness—Epirubicin—prostate cancer	5.04e-05	0.000231	CcSEcCtD
Olopatadine—Pruritus—Doxorubicin—prostate cancer	4.99e-05	0.000229	CcSEcCtD
Olopatadine—Vomiting—Epirubicin—prostate cancer	4.85e-05	0.000222	CcSEcCtD
Olopatadine—Diarrhoea—Doxorubicin—prostate cancer	4.83e-05	0.000221	CcSEcCtD
Olopatadine—Rash—Epirubicin—prostate cancer	4.81e-05	0.00022	CcSEcCtD
Olopatadine—Dermatitis—Epirubicin—prostate cancer	4.8e-05	0.00022	CcSEcCtD
Olopatadine—Headache—Epirubicin—prostate cancer	4.78e-05	0.000219	CcSEcCtD
Olopatadine—Dizziness—Doxorubicin—prostate cancer	4.66e-05	0.000214	CcSEcCtD
Olopatadine—Nausea—Epirubicin—prostate cancer	4.53e-05	0.000208	CcSEcCtD
Olopatadine—Vomiting—Doxorubicin—prostate cancer	4.48e-05	0.000206	CcSEcCtD
Olopatadine—Rash—Doxorubicin—prostate cancer	4.45e-05	0.000204	CcSEcCtD
Olopatadine—Dermatitis—Doxorubicin—prostate cancer	4.44e-05	0.000204	CcSEcCtD
Olopatadine—Headache—Doxorubicin—prostate cancer	4.42e-05	0.000203	CcSEcCtD
Olopatadine—Nausea—Doxorubicin—prostate cancer	4.19e-05	0.000192	CcSEcCtD
Olopatadine—S100B—Signaling Pathways—NOS3—prostate cancer	1.51e-05	0.000102	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NRP1—prostate cancer	1.49e-05	0.000101	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—JAK2—prostate cancer	1.47e-05	9.95e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—ADRB2—prostate cancer	1.44e-05	9.79e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MDM2—prostate cancer	1.43e-05	9.71e-05	CbGpPWpGaD
Olopatadine—S100B—Immune System—KRAS—prostate cancer	1.43e-05	9.7e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PSAT1—prostate cancer	1.42e-05	9.61e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—TST—prostate cancer	1.42e-05	9.61e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CSAD—prostate cancer	1.42e-05	9.61e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ADI1—prostate cancer	1.42e-05	9.61e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GRHL1—prostate cancer	1.42e-05	9.61e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CBR1—prostate cancer	1.42e-05	9.61e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—ERBB2—prostate cancer	1.41e-05	9.58e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—VAV3—prostate cancer	1.41e-05	9.55e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PRKCQ—prostate cancer	1.39e-05	9.45e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PIK3CB—prostate cancer	1.39e-05	9.45e-05	CbGpPWpGaD
Olopatadine—S100A12—Immune System—PIK3CA—prostate cancer	1.39e-05	9.42e-05	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—prostate cancer	1.39e-05	9.41e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—GNRH1—prostate cancer	1.38e-05	9.39e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—VIP—prostate cancer	1.38e-05	9.39e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—ITPR1—prostate cancer	1.36e-05	9.26e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—GRP—prostate cancer	1.34e-05	9.1e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—LPAR1—prostate cancer	1.34e-05	9.1e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CXCL8—prostate cancer	1.34e-05	9.08e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PLCB2—prostate cancer	1.33e-05	9e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—LRP2—prostate cancer	1.33e-05	9e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—UGT2B15—prostate cancer	1.32e-05	8.93e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GRHPR—prostate cancer	1.32e-05	8.93e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—UGT2B17—prostate cancer	1.32e-05	8.93e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CKMT2—prostate cancer	1.32e-05	8.93e-05	CbGpPWpGaD
Olopatadine—S100B—Immune System—PIK3CA—prostate cancer	1.31e-05	8.91e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—ADRB2—prostate cancer	1.31e-05	8.89e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CDKN1B—prostate cancer	1.31e-05	8.87e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—P4HB—prostate cancer	1.3e-05	8.83e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CX3CL1—prostate cancer	1.3e-05	8.83e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CASP3—prostate cancer	1.28e-05	8.69e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—IL2—prostate cancer	1.28e-05	8.68e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—VAV3—prostate cancer	1.28e-05	8.67e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HIST1H2BG—prostate cancer	1.28e-05	8.67e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—GRB7—prostate cancer	1.27e-05	8.59e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PDE4D—prostate cancer	1.27e-05	8.59e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CCND1—prostate cancer	1.25e-05	8.46e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—ITPR1—prostate cancer	1.24e-05	8.41e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—AOX1—prostate cancer	1.24e-05	8.4e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—RFK—prostate cancer	1.24e-05	8.4e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTM3—prostate cancer	1.24e-05	8.4e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PGAM2—prostate cancer	1.24e-05	8.4e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—MBTPS1—prostate cancer	1.24e-05	8.4e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NAGLU—prostate cancer	1.24e-05	8.4e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SULT2B1—prostate cancer	1.24e-05	8.4e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CTNNB1—prostate cancer	1.23e-05	8.38e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HIST1H4H—prostate cancer	1.23e-05	8.37e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR ligand binding—CXCL8—prostate cancer	1.23e-05	8.37e-05	CbGpPWpGaD
Olopatadine—S100A12—Immune System—IL6—prostate cancer	1.23e-05	8.34e-05	CbGpPWpGaD
Olopatadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—prostate cancer	1.23e-05	8.33e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MMP9—prostate cancer	1.21e-05	8.21e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—CDKN1A—prostate cancer	1.21e-05	8.18e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—GNG5—prostate cancer	1.2e-05	8.17e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PTEN—prostate cancer	1.2e-05	8.17e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP3A43—prostate cancer	1.17e-05	7.96e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SRD5A2—prostate cancer	1.17e-05	7.96e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—AMACR—prostate cancer	1.17e-05	7.96e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NAT1—prostate cancer	1.17e-05	7.96e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—DEGS1—prostate cancer	1.17e-05	7.96e-05	CbGpPWpGaD
Olopatadine—S100B—Immune System—IL6—prostate cancer	1.16e-05	7.89e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—EP300—prostate cancer	1.15e-05	7.79e-05	CbGpPWpGaD
Olopatadine—S100A12—Immune System—AKT1—prostate cancer	1.13e-05	7.7e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—HSD17B1—prostate cancer	1.12e-05	7.6e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—SRC—prostate cancer	1.12e-05	7.57e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—VEGFA—prostate cancer	1.09e-05	7.38e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—STAT3—prostate cancer	1.08e-05	7.3e-05	CbGpPWpGaD
Olopatadine—S100B—Immune System—AKT1—prostate cancer	1.07e-05	7.28e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PTHLH—prostate cancer	1.05e-05	7.12e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TGFBR1—prostate cancer	1.05e-05	7.12e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—AKR1C3—prostate cancer	1.03e-05	7e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PRKACB—prostate cancer	1.03e-05	6.97e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PPP3CA—prostate cancer	1e-05	6.79e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—THBS1—prostate cancer	1e-05	6.79e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—MYC—prostate cancer	1e-05	6.79e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—HPGD—prostate cancer	9.98e-06	6.77e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—B4GALT4—prostate cancer	9.98e-06	6.77e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TGFB1—prostate cancer	9.98e-06	6.77e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ANXA1—prostate cancer	9.86e-06	6.69e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—EGFR—prostate cancer	9.78e-06	6.64e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PRKCZ—prostate cancer	9.68e-06	6.57e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PIK3CG—prostate cancer	9.46e-06	6.42e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—TNFRSF21—prostate cancer	9.38e-06	6.37e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PARP1—prostate cancer	9.35e-06	6.34e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—FGFR4—prostate cancer	9.35e-06	6.34e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—KRAS—prostate cancer	9.24e-06	6.27e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CALCA—prostate cancer	9.24e-06	6.27e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP7B1—prostate cancer	9.13e-06	6.19e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—MTAP—prostate cancer	9.13e-06	6.19e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CXCL12—prostate cancer	9.02e-06	6.12e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SRD5A1—prostate cancer	8.89e-06	6.03e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SULT1E1—prostate cancer	8.89e-06	6.03e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PIK3CG—prostate cancer	8.59e-06	5.83e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CASP9—prostate cancer	8.5e-06	5.76e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—PIK3CA—prostate cancer	8.49e-06	5.76e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—HSD17B3—prostate cancer	8.48e-06	5.76e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ACSL4—prostate cancer	8.48e-06	5.76e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PIK3CD—prostate cancer	8.32e-06	5.64e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NGFR—prostate cancer	8.23e-06	5.59e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PRKCQ—prostate cancer	8.23e-06	5.59e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—TP53—prostate cancer	8.21e-06	5.57e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ARG2—prostate cancer	8.13e-06	5.52e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—UMPS—prostate cancer	8.13e-06	5.52e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PHGDH—prostate cancer	8.13e-06	5.52e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MAP3K7—prostate cancer	8.13e-06	5.52e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—LDHB—prostate cancer	7.98e-06	5.41e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP3A5—prostate cancer	7.83e-06	5.31e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—FGF10—prostate cancer	7.82e-06	5.31e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ADRB2—prostate cancer	7.74e-06	5.25e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—JAK2—prostate cancer	7.63e-06	5.18e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—MAP2K1—prostate cancer	7.6e-06	5.16e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PDHA1—prostate cancer	7.56e-06	5.13e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—UCP3—prostate cancer	7.56e-06	5.13e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTA3—prostate cancer	7.56e-06	5.13e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—TCN2—prostate cancer	7.56e-06	5.13e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PIK3CD—prostate cancer	7.55e-06	5.13e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—VAV3—prostate cancer	7.55e-06	5.12e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—IL6—prostate cancer	7.52e-06	5.1e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TGFBR2—prostate cancer	7.44e-06	5.05e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ITPR1—prostate cancer	7.32e-06	4.97e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PIK3CB—prostate cancer	7.25e-06	4.92e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SLC22A3—prostate cancer	7.21e-06	4.89e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—HSD3B1—prostate cancer	7.21e-06	4.89e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IGF1R—prostate cancer	7e-06	4.75e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—CXCL8—prostate cancer	6.97e-06	4.73e-05	CbGpPWpGaD
Olopatadine—S100B—Signaling Pathways—AKT1—prostate cancer	6.94e-06	4.71e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—JAK2—prostate cancer	6.93e-06	4.7e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTA4—prostate cancer	6.92e-06	4.69e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—TBXAS1—prostate cancer	6.92e-06	4.69e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTA2—prostate cancer	6.74e-06	4.57e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—LPL—prostate cancer	6.71e-06	4.55e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—IL2—prostate cancer	6.66e-06	4.52e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ABCG5—prostate cancer	6.66e-06	4.52e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SULT1A1—prostate cancer	6.66e-06	4.52e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PDGFRB—prostate cancer	6.65e-06	4.51e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PIK3CB—prostate cancer	6.58e-06	4.47e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTA1—prostate cancer	6.5e-06	4.41e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ITGB3—prostate cancer	6.48e-06	4.4e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTO1—prostate cancer	6.43e-06	4.36e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—HSD3B2—prostate cancer	6.43e-06	4.36e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NAT2—prostate cancer	6.43e-06	4.36e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—CXCL8—prostate cancer	6.33e-06	4.29e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ERBB3—prostate cancer	6.29e-06	4.27e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—FGFR2—prostate cancer	6.28e-06	4.26e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP2C18—prostate cancer	6.16e-06	4.18e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PLCB2—prostate cancer	6.16e-06	4.18e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—LRP2—prostate cancer	6.16e-06	4.18e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—IL2—prostate cancer	6.05e-06	4.1e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—P4HB—prostate cancer	6.05e-06	4.1e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TERT—prostate cancer	6.03e-06	4.09e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SLC22A1—prostate cancer	5.88e-06	3.99e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—HIF1A—prostate cancer	5.76e-06	3.91e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SULT2A1—prostate cancer	5.73e-06	3.89e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—MED12—prostate cancer	5.64e-06	3.83e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—LEP—prostate cancer	5.63e-06	3.82e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GNG5—prostate cancer	5.59e-06	3.8e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CAV1—prostate cancer	5.57e-06	3.78e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—KDR—prostate cancer	5.51e-06	3.74e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NCOA3—prostate cancer	5.39e-06	3.66e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ESR1—prostate cancer	5.37e-06	3.64e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—BAD—prostate cancer	5.24e-06	3.56e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—HPGDS—prostate cancer	5.14e-06	3.49e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP2C19—prostate cancer	5.11e-06	3.47e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—APC—prostate cancer	5.08e-06	3.44e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PIK3CG—prostate cancer	5.08e-06	3.44e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—EGF—prostate cancer	5.02e-06	3.4e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IRS1—prostate cancer	5.02e-06	3.4e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTT1—prostate cancer	4.99e-06	3.38e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ACHE—prostate cancer	4.99e-06	3.38e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP2A6—prostate cancer	4.93e-06	3.34e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—GSK3B—prostate cancer	4.87e-06	3.31e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—INS—prostate cancer	4.81e-06	3.26e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—AKR1C3—prostate cancer	4.79e-06	3.25e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PRKACB—prostate cancer	4.77e-06	3.24e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP17A1—prostate cancer	4.72e-06	3.2e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CREBBP—prostate cancer	4.71e-06	3.19e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IGF1—prostate cancer	4.65e-06	3.15e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—EGFR—prostate cancer	4.63e-06	3.14e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NCOA2—prostate cancer	4.5e-06	3.05e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MAP2K1—prostate cancer	4.49e-06	3.05e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PIK3CD—prostate cancer	4.46e-06	3.03e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—PIK3CA—prostate cancer	4.42e-06	3e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SERPINE1—prostate cancer	4.41e-06	2.99e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—KRAS—prostate cancer	4.37e-06	2.96e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—SLC5A5—prostate cancer	4.29e-06	2.91e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—FGF2—prostate cancer	4.27e-06	2.9e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—NOS3—prostate cancer	4.21e-06	2.86e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP2E1—prostate cancer	4.19e-06	2.84e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NQO1—prostate cancer	4.14e-06	2.81e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—JAK2—prostate cancer	4.1e-06	2.78e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—TH—prostate cancer	4.08e-06	2.77e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—PIK3CA—prostate cancer	4.01e-06	2.72e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MDM2—prostate cancer	4e-06	2.71e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP1B1—prostate cancer	3.97e-06	2.7e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—ERBB2—prostate cancer	3.94e-06	2.67e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PIK3CB—prostate cancer	3.89e-06	2.64e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GGT1—prostate cancer	3.85e-06	2.61e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NCOA1—prostate cancer	3.79e-06	2.57e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CXCL8—prostate cancer	3.74e-06	2.54e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP19A1—prostate cancer	3.74e-06	2.53e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CDKN1B—prostate cancer	3.65e-06	2.48e-05	CbGpPWpGaD
Olopatadine—HRH1—GPCR downstream signaling—AKT1—prostate cancer	3.61e-06	2.45e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—RXRA—prostate cancer	3.6e-06	2.45e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CASP3—prostate cancer	3.58e-06	2.43e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IL2—prostate cancer	3.57e-06	2.42e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—IL6—prostate cancer	3.55e-06	2.41e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CCND1—prostate cancer	3.48e-06	2.36e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—COMT—prostate cancer	3.47e-06	2.36e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTP1—prostate cancer	3.46e-06	2.34e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CTNNB1—prostate cancer	3.45e-06	2.34e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ITPR1—prostate cancer	3.4e-06	2.31e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MMP9—prostate cancer	3.38e-06	2.29e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—CDKN1A—prostate cancer	3.37e-06	2.29e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PTEN—prostate cancer	3.36e-06	2.28e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling by GPCR—AKT1—prostate cancer	3.28e-06	2.22e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—TYMS—prostate cancer	3.21e-06	2.18e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—EP300—prostate cancer	3.21e-06	2.17e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—GSTM1—prostate cancer	3.18e-06	2.15e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—LPL—prostate cancer	3.12e-06	2.12e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—SRC—prostate cancer	3.12e-06	2.11e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—VEGFA—prostate cancer	3.04e-06	2.06e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CYP1A1—prostate cancer	3.01e-06	2.04e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—STAT3—prostate cancer	3.01e-06	2.04e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—ERCC2—prostate cancer	2.99e-06	2.03e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—MTHFR—prostate cancer	2.81e-06	1.9e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—MYC—prostate cancer	2.79e-06	1.9e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TGFB1—prostate cancer	2.79e-06	1.89e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PPARA—prostate cancer	2.75e-06	1.87e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—EGFR—prostate cancer	2.73e-06	1.85e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CAV1—prostate cancer	2.59e-06	1.76e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—KRAS—prostate cancer	2.58e-06	1.75e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—PIK3CA—prostate cancer	2.37e-06	1.61e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PIK3CG—prostate cancer	2.36e-06	1.6e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—TP53—prostate cancer	2.29e-06	1.56e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—INS—prostate cancer	2.23e-06	1.51e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—CREBBP—prostate cancer	2.19e-06	1.48e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—IL6—prostate cancer	2.1e-06	1.42e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.07e-06	1.41e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—NOS3—prostate cancer	1.96e-06	1.33e-05	CbGpPWpGaD
Olopatadine—HRH1—Signaling Pathways—AKT1—prostate cancer	1.94e-06	1.31e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.81e-06	1.23e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PTGS2—prostate cancer	1.79e-06	1.21e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PTEN—prostate cancer	1.56e-06	1.06e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—EP300—prostate cancer	1.49e-06	1.01e-05	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.1e-06	7.47e-06	CbGpPWpGaD
Olopatadine—CYP3A4—Metabolism—AKT1—prostate cancer	9e-07	6.11e-06	CbGpPWpGaD
